PapersFlow Research Brief
Otitis Media and Relapsing Polychondritis
Research Guide
What is Otitis Media and Relapsing Polychondritis?
Otitis Media and Relapsing Polychondritis refers to a research cluster encompassing Relapsing Polychondritis, a rare autoimmune disease characterized by recurrent inflammation of cartilage and other tissues, and studies on VEXAS syndrome, an autoinflammatory condition linked to somatic UBA1 mutations.
The field includes 13,173 papers on clinical features, disease activity, therapeutic options, and somatic mutations in Relapsing Polychondritis and VEXAS syndrome. Research covers cartilage autoimmunity, biological drug use, and associations with vasculitides nomenclature. Growth rate over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Clinical Features of Relapsing Polychondritis
Researchers characterize auricular chondritis, nasal saddle deformity, and tracheobronchial involvement through cohort studies and imaging. Studies correlate phenotypes with disease trajectories and comorbidities.
VEXAS Syndrome Pathogenesis
This area investigates UBA1 somatic mutations driving autoinflammation, using genomic sequencing and functional assays. Research links mutations to neutrophil dysregulation and chondritis.
Therapeutic Options in Relapsing Polychondritis
Studies evaluate corticosteroids, immunosuppressants, and biologics like anti-TNF and IL-6 inhibitors in observational cohorts. Outcome measures include relapse rates and organ-specific responses.
Disease Activity Assessment in Relapsing Polychondritis
Researchers validate scores like RP Activity Index incorporating clinical, lab, and imaging parameters. Longitudinal data refine tools for trial endpoints and monitoring.
Somatic Mutations in Autoinflammatory Rheumatic Diseases
This subfield explores UBA1 and other somatic variants in polychondritis-like syndromes via deep sequencing. Functional studies elucidate inflammasome activation and therapeutic implications.
Why It Matters
Classification criteria from related vasculitides and rheumatic conditions aid diagnosis of Relapsing Polychondritis manifestations, such as ear cartilage inflammation resembling otitis media. Jennette et al. (2012) in "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" standardized terms for over 35 vasculitides, enabling precise identification of polychondritis overlaps, with 6357 citations reflecting its impact. Hunder et al. (1990) criteria for giant cell arteritis achieved 93.5% sensitivity and 91.2% specificity in classifying 214 patients, supporting differential diagnosis in autoinflammatory syndromes like VEXAS.
Reading Guide
Where to Start
"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" by Jennette et al. (2012), as it provides foundational standardized terms for vasculitides overlapping with Relapsing Polychondritis features, cited 6357 times.
Key Papers Explained
Jennette et al. (2012) in "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides" establishes nomenclature linking to polychondritis. Hunder et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis" builds diagnostic precision for related cranial arteritis. Masi et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome" and Leavitt et al. (1990) in "The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis" extend classification frameworks for eosinophilic and granulomatous overlaps.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on VEXAS syndrome UBA1 mutations and biological therapies, as no recent preprints or news cover new developments.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | 2012 Revised International Chapel Hill Consensus Conference No... | 2012 | Arthritis & Rheumatism | 6.4K | ✓ |
| 2 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.5K | ✕ |
| 3 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.2K | ✕ |
| 4 | The American College of Rheumatology 1990 criteria for the cla... | 1990 | Arthritis & Rheumatism | 2.0K | ✕ |
| 5 | Preliminary criteria for classification of adult Still's disease. | 1992 | PubMed | 1.8K | ✕ |
| 6 | Allergic granulomatosis, allergic angiitis, and periarteritis ... | 2004 | PubMed | 1.7K | ✕ |
| 7 | Behçet's Disease | 1999 | New England Journal of... | 1.6K | ✕ |
| 8 | The International Criteria for Behçet's Disease (ICBD): a coll... | 2013 | Journal of the Europea... | 1.4K | ✓ |
| 9 | Polymyalgia Rheumatica and Giant-Cell Arteritis | 2002 | New England Journal of... | 1.3K | ✓ |
| 10 | Trial of Tocilizumab in Giant-Cell Arteritis | 2017 | New England Journal of... | 1.3K | ✓ |
Frequently Asked Questions
What is Relapsing Polychondritis?
Relapsing Polychondritis is a rare autoimmune disease with recurrent inflammation of cartilage and other tissues. It associates with VEXAS syndrome due to somatic UBA1 mutations. Studies examine its clinical features and disease activity.
How are classification criteria used for vasculitides in Relapsing Polychondritis?
Jennette et al. (2012) revised nomenclature for vasculitides in "2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides." This standardizes terms for conditions overlapping with polychondritis cartilage inflammation. It received 6357 citations.
What role do somatic mutations play in VEXAS syndrome?
VEXAS syndrome is an autoinflammatory condition tied to somatic mutations in UBA1. These mutations contribute to Relapsing Polychondritis features like cartilage autoimmunity. Research covers therapeutic options targeting these pathways.
What are key clinical features of related conditions?
Hunder et al. (1990) defined criteria for giant cell arteritis including age ≥50 years, with 93.5% sensitivity in 214 patients. Similar criteria apply to polychondritis differentials like Churg-Strauss syndrome. These aid in distinguishing otitis media-like ear involvement.
Which therapies are studied for these diseases?
Papers explore biological drug use in Relapsing Polychondritis and VEXAS. Stone et al. (2017) showed tocilizumab with prednisone taper achieved sustained remission in giant cell arteritis. This informs options for polychondritis disease activity.
Open Research Questions
- ? How do UBA1 somatic mutations mechanistically drive cartilage inflammation in Relapsing Polychondritis and VEXAS?
- ? What specific diagnostic criteria best distinguish Relapsing Polychondritis ear involvement from infectious otitis media?
- ? Which biological therapies most effectively control recurrent polychondritis flares?
- ? How frequently does VEXAS syndrome overlap with vasculitides classified by Jennette et al. (2012)?
- ? What biomarkers predict disease activity in polychondritis patients?
Recent Trends
The field maintains 13,173 papers with no specified 5-year growth rate.
Top-cited works like Jennette et al. with 6357 citations continue dominating, emphasizing classification criteria.
2012No recent preprints or news indicate ongoing stasis in VEXAS and polychondritis research.
Research Otitis Media and Relapsing Polychondritis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Otitis Media and Relapsing Polychondritis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers